Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented ...

A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Shares of Regeneron Pharmaceuticals Inc. REGN slumped 0.17% to $1,012.82 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...